Background/aim: Aldehyde dehydrogenase-1A1 (ALDH1A1) and CD133 have been identified as markers of cancer stem cells (CSCs). We investigated the expression of these markers and their clinical significance in lung adenocarcinoma.
Materials And Methods: An immunohistochemical analysis of ALDH1A1 and CD133 expression of 92 lung adenocarcinomas was performed. The association between the expression of both markers and cancer-related death and recurrence was determined.
Results: Cancer-related death and tumor recurrence were observed in 15 and 17 cases, respectively. The expression of CD133, but not ALDHA1A, was significantly associated with poorer overall survival (p<0.0001) and shorter disease-free interval (DFI) (p<0.0001). Multivariate analysis revealed that double negativity was independently associated with increased survival (hazard ratio(HR)=16.1, p=0.0004) and a longer DFI (HR=9.5, p=0.0007).
Conclusion: We propose that as a functional marker, ALDH1A1 positivity may influence the viability of CSCs. The findings suggest that it is important to evaluate the expression of both markers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.11597 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structure-Based identification of a potent KDM7A inhibitor exerts anticancer activity through transcriptionally reducing MKRN1 in taxol- resistant and -sensitive triple-negative breast cancer cells.
Bioorg Chem
December 2024
State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products, School of Marine Sciences, Ningbo University, Ningbo 315211, Zhejiang, China. Electronic address:
Article Synopsis
- * Virtual screening of over 100,000 compounds identified 12 potential inhibitors, with compound 4 showing the most promise in blocking KDM7A's activity, leading to reduced breast cancer stem cells and cell cycle arrest.
- * The research also highlights MKRN1 as a significant gene influenced by KDM7A, further revealing the potential of compound 4 as an effective treatment option for both drug-resistant and sensitive triple-negative breast cancer.
[ALDH1, CD133, CD34-positive cancer stem cells in lung adenocarcinoma in patients who had a new coronavirus infection and retained the persistence of viral proteins in the lung tissue].
Arkh Patol
October 2024
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Article Synopsis
- Lung cancer is a major global health issue, influenced by cancer stem cells (CSCs), but the interaction between these CSCs and SARS-CoV2 is not well understood.
- This study compares lung adenocarcinoma samples from 12 patients who had COVID-19 with 12 who did not, examining tumor characteristics and CSC markers.
- Results indicated that patients who had COVID-19 had significantly more CSCs (marked by ALDH1, CD133, and CD34) in their tumors, suggesting that COVID-19 may enhance the metastatic potential of lung adenocarcinoma and the presence of viral proteins in the lung tissue.
Oncogenic fusion of CD63-BCAR4 contributes cancer stem cell-like properties via ALDH1 activity.
Mol Carcinog
December 2024
College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea.
Gene fusions are common somatic alterations in cancers, and fusions with tumorigenic features have been identified as novel drivers of cancer and therapeutic targets. Few studies have determined whether the oncogenic ability of fusion genes is related to the induction of stemness in cells. Cancer stem cells (CSCs) are a subset of cells that contribute to cancer progression, metastasis, and recurrence, and are critical components of the aggressive features of cancer.
View Article and Find Full Text PDFCD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
Breast Cancer Res Treat
November 2024
Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY, 14263, USA.
Purpose: CD133, a cancer stem cells (CSC) marker, has been reported to be associated with treatment resistance and worse survival in triple-negative breast cancer (BC). However, the clinical relevance of CD133 expression in ER-positive/HER2-negative (ER + /HER2-) BC, the most abundant subtype, remains unknown.
Methods: The BC cohorts from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n = 1904) and The Cancer Genome Atlas (TCGA, n = 1065) were used to obtain biological variables and gene expression data.
Purpose: CD133, a cancer stem cells (CSC) marker, has been reported to be associated with treatment resistance and worse survival in triple-negative breast cancer (BC). However, the clinical relevance of CD133 expression in ER-positive/HER2-negative (ER+/HER2-) BC, the most abundant subtype, remains unknown.
Methods: The BC cohorts from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n = 1904) and The Cancer Genome Atlas (TCGA, n = 1065) were used to obtain biological variables and gene expression data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!